B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors

BACKGROUND: Not all lung adenocarcinoma (LUAD) patients with activating epidermal growth factor receptor (EGFR) mutations respond to tyrosine kinase inhibitors (TKIs) as intended. Thus, biomarkers are needed to identify patients who benefit most from EGFR-targeted therapy. Our previous in vitro data...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ying, Huang, Jun-feng, Hu, Bing-qi, Zhou, Jing, Wang, Xian, Feng, Zhen-zhong, Chen, Yu-ting, Pan, Fa-ming, Cheng, Huai-dong, Chen, Li-wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121599/
https://www.ncbi.nlm.nih.gov/pubmed/35590371
http://dx.doi.org/10.1186/s12957-022-02634-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121599/
https://www.ncbi.nlm.nih.gov/pubmed/35590371
http://dx.doi.org/10.1186/s12957-022-02634-x

Ejemplares similares